Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents
EuroInterv.2007;3:213-221.
Keith D. Dawkins1*, MD, FRCP, FACC; Eberhard Grube2, MD, PhD, FACA, FACC, FSCAI; Giulio Guagliumi3, MD, FESC; Adrian P Banning4, MD, FRCP, FESC; Krzysztof Zmudka5, MD, PhD; Antonio Colombo6, MD, FACC, FESC; Leif Thuesen7, MD, FESC; Karl Hauptman8, MD; Jean Marco9, MD FESC, FACC; William Wijns10, MD, PhD, FESC; Jeffrey J Popma11, MD, FACC; Neil J. Weissman12, MD, FACC; Joerg Koglin13, MD, FACC; Mary E Russell13, MD, FACC; on behalf of the TAXUS VI investigators
1. Southampton University Hospital, Southampton, United Kingdom; 2. Krankenhaus Siegburg, Siegburg, Germany; 3. Ospedali Riuniti di Bergamo, Bergamo, Italy; 4. John Radcliffe Hospital, Oxford, United Kingdom; 5. Jan Pawel II Hospital, International Cardio
Aims: To provide insight on the patients with long lesions that received multiple, overlapping stents by reporting clinical outcomes, together with a detailed angiographic and intravascular